Biotech News
Windward Bio Launches with $200M Backing to Advance WIN378 for Severe Asthma
Windward Bio has officially launched, announcing the close of a $200 million Series A financing round. The funding is led by OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities, alongside co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners,
17 January 2025
Stay ahead of trends and best practices
